Vaccine company Eurocine Vaccines AB reported on Thursday the completion of dosing this week under its planned second clinical study of its quadrivalent influenza vaccine candidate, Immunose FLU.
The company said the Immunose FLU was developed with the aim to become a modern and effective nasal influenza vaccine.
According to CSO Dr Anna-Karin Maltais, the company has chosen the broader quadrivalent, rather than trivalent, vaccine for its product candidate following this year's severe influenza outburst.
Additionally, the elderly always suffer most from influenza disease and Immunose FLU can offer a better and more convenient vaccine in this segment. It also plans to offer the first nasal influenza vaccine for children younger than two years, adds Hans Arwidsson, CEO of Eurocine Vaccines.
In conjunction, the strategy behind this present study and its design was presented in February 2018. The results are expected in second half of 2018, concluded the company.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100